Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CBX7 | O95931 | 2/20 | 0.38 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.38 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782243 | 0.86 | NAMPT (0.47) | NAMPTKMOMCL1HPGDPTGDR2 | |
| SCHEMBL29456302 | 0.82 | LMNA (0.41) | SCN7AKCNH2CBX7CDYLHPGD | |
| SCHEMBL347208 | 0.82 | MAPT (0.45) | KMOSCN7AKCNH2MAPTTP53 | |
| SCHEMBL3776134 | 0.81 | NAMPT (0.47) | NAMPTMCL1MAPTNTSR1TP53 | |
| SCHEMBL3785882 | 0.79 | KDM4E (0.51) | NAMPTMAPT | |
| SCHEMBL3782016 | 0.78 | MAPK9 (0.52) | MAPK9 | |
| SCHEMBL21196908 | 0.78 | SCN7A (0.55) | KMOSCN7AKCNH2CDY1; CDY1BMAPK9 | |
| SCHEMBL29456267 | 0.78 | MAPK9 (0.52) | MAPK9 | |
| SCHEMBL29456342 | 0.77 | MAPK9 (0.46) | SCN7AKCNH2MAPK9HPGDHTR2A | |
| SCHEMBL14689475 | 0.76 | TSPO (0.54) | MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015977-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-01-19 | — | — | US | claimed |
| EP-2387562-A1 | Quinolinone derivatives useful for the treatment of cns disorders | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | claimed |
| WO-2010081900-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | claimed |
| US-20120015977-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-01-19 | — | — | US | disclosed |
| EP-2387562-A1 | Quinolinone derivatives useful for the treatment of cns disorders | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | disclosed |
| WO-2010081900-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015977-A1 | QUINOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | AQP4, PMP22, CHRNA2 | NAMPT 1834/4885KMO 767/4885SCN7A 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.